Benitec Biopharma Inc.
BNTC
$11.50
-$0.18-1.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.17% | 191.61% | 562.13% | 166.67% | 197.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.80% | 69.28% | 209.59% | 146.03% | 55.98% |
| Operating Income | -23.80% | -69.28% | -209.59% | -146.03% | -55.98% |
| Income Before Tax | -23.92% | -77.21% | -242.10% | -118.60% | -40.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.92% | -77.21% | -242.10% | -118.60% | -40.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.92% | -77.21% | -242.10% | -118.60% | -40.51% |
| EBIT | -23.80% | -69.28% | -209.59% | -146.03% | -55.98% |
| EBITDA | -23.83% | -69.79% | -210.79% | -147.21% | -56.16% |
| EPS Basic | -0.43% | -19.02% | -114.61% | -3.50% | 90.28% |
| Normalized Basic EPS | 7.05% | -18.96% | -114.71% | -3.55% | 89.50% |
| EPS Diluted | -0.43% | -19.02% | -114.61% | -3.50% | 90.28% |
| Normalized Diluted EPS | 7.05% | -18.96% | -114.71% | -3.55% | 89.50% |
| Average Basic Shares Outstanding | 23.39% | 48.91% | 59.36% | 111.14% | 1,346.06% |
| Average Diluted Shares Outstanding | 23.39% | 48.91% | 59.36% | 111.14% | 1,346.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |